Alport Syndrome Clinical Trials

37 clinical trials for Alport Syndrome across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome — RECRUITING · PHASE2
• Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE) — RECRUITING
• NEPTUNE Match Study — RECRUITING · NA
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases — RECRUITING · PHASE2
• ASF Alport Patient Registry — RECRUITING
• Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport) — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY WITH AN EXTENSION PHASE TO EVALUATE THE EFFICACY AND SAFETY OF BAY 3401016 IN PARTICIPANTS AGED 18 TO 45 WITH ALPORT SYNDROME — RECRUITING · PHASE2
• Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome — RECRUITING
• National Registry of Rare Kidney Diseases — RECRUITING
• Genotype-Phenotype Correlations in Patients With Alport Syndrome — RECRUITING
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF LADEMIRSEN (SAR339375) FOR SUBCUTANEOUS INJECTION ADMINISTERED EVERY WEEK IN PATIENTS WITH ALPORT SYNDROME (HERA) — RECRUITING · PHASE2
• A PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME — RECRUITING · PHASE2
• DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dapagliflozin on the progression of chronic kidney disease in adolescent and young adult patients with Alport syndrome — TERMINATED · PHASE3
• Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT) — COMPLETED · PHASE4
• Atrasentan in Patients With Proteinuric Glomerular Diseases — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate Setanaxib in Patients With Alport Syndrome — COMPLETED · PHASE1
• A Study of ELX-02 in Patients With Alport Syndrome — COMPLETED · PHASE2
• Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) — COMPLETED · PHASE2
• Alport Syndrome Treatments and Outcomes Registry — COMPLETED
• Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome — OTHER · PHASE2
• Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis — COMPLETED · PHASE2
• Study of Lademirsen (SAR339375) in Patients With Alport Syndrome — TERMINATED · PHASE2
• Baby Detect : Genomic Newborn Screening — COMPLETED
• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL — COMPLETED · PHASE2
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) — TERMINATED · PHASE3
• A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients with Alport Syndrome — OTHER · PHASE2
• Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome — NOT_YET_RECRUITING · PHASE2
• Effects of Dapagliflozin on Progression of Alport Syndrome — ACTIVE_NOT_RECRUITING
• Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome — COMPLETED · PHASE2
• Treatment With Metformin in Chinese Children With Alport Syndrome — OTHER · PHASE4
• A Study of RG-012 in Subjects With Alport Syndrome — COMPLETED · PHASE1
• Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants — NOT_YET_RECRUITING · NA
• A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome — COMPLETED
• Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study — COMPLETED
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS, PHARMACOKINETICS, DOSE SELECTION, AND PRELIMINARY EFFICACY OF WEEKLY RG-012 INJECTIONS IN PATIENTS WITH ALPORT SYNDROME. — NOT_YET_RECRUITING · PHASE2
• Human Urine Sample Collection for Alport Nephropathy Biomarker Studies — TERMINATED
• Urinary Biomarkers of the Progression of Alport Kidney Disease — COMPLETED

Refine this search